Helus Pharma notches successful Phase 3 depression readout
Helus Pharma, part of the budding class of psychedelics companies, said its lead drug improved depression symptoms compared to placebo, but investors appeared slightly skittish about the safety profile. The company said
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.